gptkbp:instance_of
|
gptkb:pharmaceuticals
|
gptkbp:approves
|
gptkb:European_Union
gptkb:South_Korea
gptkb:United_States
|
gptkbp:bioequivalence
|
gptkb:Remicade
|
gptkbp:class
|
immunomodulator
|
gptkbp:clinical_trial
|
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis
gptkb:ankylosing_spondylitis
psoriasis
Phase III trials
|
gptkbp:contraindication
|
heart failure
active infections
hypersensitivity to infliximab
|
gptkbp:developed_by
|
gptkb:Celltrion
|
gptkbp:dosage_form
|
solution for infusion
|
gptkbp:drug_interactions
|
immunosuppressants
live vaccines
|
gptkbp:duration
|
varies by condition
|
gptkbp:effective_date
|
gptkb:2013
|
gptkbp:events
|
regular monitoring
|
gptkbp:financial_support
|
available
|
gptkbp:formulation
|
lyophilized powder
|
https://www.w3.org/2000/01/rdf-schema#label
|
Remsima
|
gptkbp:ingredients
|
infliximab
|
gptkbp:invention
|
patented
|
gptkbp:is_effective_against
|
demonstrated in studies
|
gptkbp:launch_date
|
gptkb:2015
|
gptkbp:manufacturer
|
gptkb:Celltrion_Healthcare
|
gptkbp:marketed_as
|
multiple countries
biosimilar to Remicade
|
gptkbp:mechanism_of_action
|
TNF-alpha inhibitor
|
gptkbp:patient_education
|
important for adherence
|
gptkbp:patient_population
|
gptkb:children
adults
|
gptkbp:pharmacovigilance
|
ongoing monitoring
|
gptkbp:price
|
varies by region
|
gptkbp:provides_guidance_on
|
included in treatment guidelines
|
gptkbp:reconstitution_required
|
gptkb:true
|
gptkbp:regulatory_compliance
|
approved
|
gptkbp:research_and_development
|
ongoing
|
gptkbp:route_of_administration
|
intravenous infusion
|
gptkbp:safety_features
|
well-studied
|
gptkbp:sales
|
increasing
|
gptkbp:side_effect
|
headache
nausea
abdominal pain
infections
infusion reactions
|
gptkbp:storage
|
refrigerated
|
gptkbp:supply_chain
|
managed by Celltrion
|
gptkbp:training
|
recommended
|
gptkbp:used_for
|
treatment of autoimmune diseases
|
gptkbp:website
|
intravenous
|
gptkbp:bfsParent
|
gptkb:Celltrion
|
gptkbp:bfsLayer
|
6
|